PART I Overview We are a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. Our lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT). The product is designed to eliminate residual di...
Q2 FY2026 — expected 2026-09-10
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-04 | 2025-12-31 | 0001193125-26-089884 | EDGAR | 109K words |
| 2025-03-05 | 2024-12-31 | 0000950170-25-033077 | EDGAR | — |
| 2024-03-06 | 2023-12-31 | 0000950170-24-026875 | EDGAR | — |
| 2023-03-08 | 2022-12-31 | 0000950170-23-006589 | EDGAR | — |
| 2022-03-09 | 2021-12-31 | 0000950170-22-003175 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001193125-25-275933 | EDGAR | 71K words |
| 2025-08-12 | 2025-06-30 | 0000950170-25-106919 | EDGAR | — |
| 2025-05-06 | 2025-03-31 | 0000950170-25-063968 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0000950170-24-124575 | EDGAR | — |
| 2024-08-12 | 2024-06-30 | 0000950170-24-095066 | EDGAR | — |
| 2024-05-13 | 2024-03-31 | 0000950170-24-058198 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0000950170-23-061533 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0000950170-23-040961 | EDGAR | — |
| 2023-05-10 | 2023-03-31 | 0000950170-23-020087 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0000950170-22-023507 | EDGAR | — |
| 2022-08-10 | 2022-06-30 | 0000950170-22-016263 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0000950170-22-009472 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-02 | 0001193125-26-138973 | EDGAR | 1K words |
| 2026-03-04 | 0001193125-26-089871 | EDGAR | — |
| 2026-01-12 | 0001193125-26-009771 | EDGAR | — |
| 2025-11-26 | 0001193125-25-300538 | EDGAR | — |
| 2025-11-12 | 0001193125-25-275889 | EDGAR | — |
| 2025-11-03 | 0001193125-25-261612 | EDGAR | — |
| 2025-09-09 | 0001193125-25-198768 | EDGAR | — |
| 2025-08-20 | 0001193125-25-184083 | EDGAR | — |
| 2025-08-12 | 0000950170-25-106915 | EDGAR | — |
| 2025-07-02 | 0001193125-25-154336 | EDGAR | — |
98 total filings indexed. 71 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001783328 |
| Ticker | TCRX |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.tscan.com |
| Listed | 2021-07-16 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report